Pipeline

  • NuGel® has shown significant improvement in atopic dermatitis by normalizing TH1/TH2 balance, inhibiting pro-inflammatory responses and reconstructing skin integrity through up-regulating expression of various matrix proteins.
  • NuSepin® globally edits the proteome to increase the number of gMDSCs (granulocytic myeloid-derived suppressor cells) and enhance their immune-regulatory functions to resolve systemic inflammation during sepsis.
  • NuCerin® reduces brain inflammation by decreasing loads of Aβ plaques, number of activated microglia, reactive astrocytes, iNOS expression, and TUNEL(+) apoptotic cells in the frontal cortex of 5XFAD mice.
  • NuColin® improves colitis symptoms by decreasing production of pro-inflammatory cytokines such as IL-6, IL-1β, TNF-α in DSS colitis model in addition to down-regulating immune cell recruitment in inflamed colon tissues.
  • Under affinity maturation
  • Under affinity maturation
  • Under affinity maturation
  • NuPrin® significantly suppresses itch sensation without triggering inflammatory responses in the skin which is usual side-effect of classical anti-pruritic drugs in the market.
  • In cancer environment NuBoost® significantly decreases MDSCs without deleting T cells or B cells in a dose range far less than cytotoxic to other stromal cells.
  • TAA388 fused with protein transduction domain enhances DC-based immunotherapy for patients carrying TAA388+ cancers.